Isn't the whole point of any listed biotech ongoing scientific research into whatever field they choose to specialise in? In EX1's case they will likely be purchased by big pharma for multiple billion $ before even reaching the FDA stage, given their field of research.
Codiak ($800mil market capitalisation), page-178
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $20.69M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.9¢ | $18.75K | 951.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 183839 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1000000 | 1 |
View Market Depth
| Last trade - 11.43am 11/10/2024 (20 minute delay) ? |
| TYP (ASX) Chart |